UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 143

Sortiert nach

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

The American journal of psychiatry, 2008-08, Vol.165 (8), p.1033-1039

2008

Link zum Volltext

Verfügbarkeit prüfen

The Discovery of Fluoxetine Hydrochloride (Prozac)

Nature reviews. Drug discovery, 2005-09, Vol.4 (9), p.764-774

2005

Link zum Volltext

Verfügbarkeit prüfen

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

Pharmacological reviews, 2008-09, Vol.60 (3), p.358

2008

Link zum Volltext

Verfügbarkeit prüfen

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Neuropharmacology, 2006-05, Vol.50 (6), p.755-760

2006

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

Synapse (New York, N.Y.), 2012-06, Vol.66 (6), p.522-532

2012

Link zum Volltext

Verfügbarkeit prüfen

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

Psychopharmacology, 2013-03, Vol.226 (2), p.189-200

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

The Journal of pharmacology and experimental therapeutics, 2002-06, Vol.301 (3), p.1020

2002

Link zum Volltext

Verfügbarkeit prüfen

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

British journal of pharmacology, 2003-02, Vol.138 (4), p.544-553

2003

Link zum Volltext

Verfügbarkeit prüfen

Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates

PloS one, 2015-04, Vol.10 (4), p.e0122722-e0122722

2015

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Journal of medicinal chemistry, 2000-11, Vol.43 (23), p.4333-4353

2000

Link zum Volltext

Verfügbarkeit prüfen

Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system

Neurochemical research, 2003-04, Vol.28 (3-4), p.437-442

2003

Link zum Volltext

Verfügbarkeit prüfen

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Neuropsychopharmacology (New York, N.Y.), 1996-02, Vol.14 (2), p.87-96

1996

Link zum Volltext

Verfügbarkeit prüfen

Muscarinic mechanisms in psychotic disorders

Handbook of experimental pharmacology, 2012 (213), p.233

2012

Link zum Volltext

Verfügbarkeit prüfen

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity

The European journal of neuroscience, 2003-04, Vol.17 (7), p.1403-1410

2003

Link zum Volltext

Verfügbarkeit prüfen

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity

Synapse (New York, N.Y.), 2012-05, Vol.66 (5), p.435-444

2012

Link zum Volltext

Verfügbarkeit prüfen

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Neuropsychopharmacology (New York, N.Y.), 2002-11, Vol.27 (5), p.699-711

2002

Link zum Volltext

Verfügbarkeit prüfen

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat

Neuropharmacology, 2004-02, Vol.46 (2), p.232-242

2004

Link zum Volltext

Verfügbarkeit prüfen

Case history: the discovery of fluoxetine hydrochloride (Prozac)

Nature reviews. Drug discovery, 2005-09, Vol.4 (9), p.764-774

2005

Link zum Volltext

Verfügbarkeit prüfen

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Neuropsychopharmacology, 2003-09, Vol.28 (9), p.1685-1693

2003

Link zum Volltext

Verfügbarkeit prüfen

Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder

Journal of experimental pharmacology, 2024, Vol.16, p.13-24

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Neuropsychopharmacology (New York, N.Y.), 2001-12, Vol.25 (6), p.871-880

2001

Link zum Volltext

Verfügbarkeit prüfen

Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

European journal of pharmacology, 2001-11, Vol.430 (2-3), p.341-349

2001

Link zum Volltext

Verfügbarkeit prüfen

Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease

Proceedings of the National Academy of Sciences - PNAS, 2001-12, Vol.98 (25), p.14669-14674

2001

Link zum Volltext

Verfügbarkeit prüfen

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

Current pharmaceutical design, 2005-05, Vol.11 (12), p.1475

2005

Link zum Volltext

Verfügbarkeit prüfen

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Psychopharmacologia, 2002-04, Vol.160 (4), p.353-361

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 143

Suche als RSS-Feed

Aktive Filter

KollektionApplied Social Sciences Index & Abstracts (ASSIA)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(124)

Publikationsform

Artikel
(142)
Buchkapitel
(1)

Sprache

Englisch
(143)
Japanisch
(36)

Erscheinungsjahr

n.n

Thema

Science & Technology
(89)
Animals
(85)
Life Sciences & Biomedicine
(85)
Pharmacology & Pharmacy
(62)
Male
(56)
Biological And Medical Sciences
(50)
Rats
(48)
Medical Sciences
(43)
Humans
(42)
Pharmacology. Drug Treatments
(39)
Neuropharmacology
(37)
Neurosciences & Neurology
(31)
Neurosciences
(30)
Mice
(29)
Psychology. Psychoanalysis. Psychiatry
(26)
Psychopharmacology
(26)
Dose-Response Relationship, Drug
(24)
Muscarinic Agonists - Pharmacology
(22)
Rats, Sprague-Dawley
(21)
Psychiatry
(20)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

The Discovery of Fluoxetine Hydrochloride (Prozac)

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Muscarinic mechanisms in psychotic disorders

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat

Case history: the discovery of fluoxetine hydrochloride (Prozac)

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Aktive Filter

Suchergebnisse filtern